clinical trial · NCT07473752
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
Tonix Pharmaceuticals, Inc.·phase1·completed·n = 26
Phase 1 First-in-human Study Involving Healthy SubjectsTNX-1500Placebo: USP 0.9% sterile saline for injectionKeyhole Limpet Hemocyanin (KLH)
brief summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects
started
Jul 18, 2023
primary completion
Feb 22, 2024
completion
Feb 22, 2024
last updated
Mar 16, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol